1
|
Del Río-Álvarez Á, Carrillo-Reixach J, Royo L, Domingo-Sàbat M, Azkargorta M, Kapler R, Cairo S, Vokuhl C, de Krijger R, Alaggio R, Garrido M, Guillen G, Sábado C, Guerra L, Hernandez F, Mateos ME, López-Satamaría M, Torres B, Abad MP, Viera B, Czauderna P, Buendia MA, Elortza F, Wheatley K, Morland B, Armengol C. Abstract PO011: Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers. Clin Cancer Res 2022. [DOI: 10.1158/1557-3265.liverca22-po011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Childhood liver cancers hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are rare diseases but with a rising incidence. HEMNOS (Hepatocellular malignant neoplasm, not otherwise specified) is a recent entity with histopathological features of HB and HCC. Current chemotherapy treatments are effective to shrink tumor before surgery, nonetheless can cause severe lifelong adverse effects and are not effective for patients with aggressive and metastatic HB or HCC (~20% die due to the disease). The HB and HCC diagnosis is key to assign therapeutic regimens in the ongoing Pediatric Hepatic International Tumor Trial (PHITT); however, differential diagnosis for some patients is challenging due to the lack of specific biomarkers. Nowadays, there is an urgent need to identify diagnostic and prognostic biomarkers to improve the clinical management of childhood liver cancer. Herein, we aimed to uncover the proteomic profiles of different types of childhood liver cancer and identify new biomarkers for improving tumor diagnosis and early detection of the most aggressive cases. For this, 99 frozen tissue samples from 71 patients (mean age: 54.5 months, 60.6% boys, 40.9% metastasis, 23.7% deaths) including 70 primary tumors (57 HB, 8 HCC and 5 HEM-NOS), 22 non-tumors and 7 metastases were analyzed by label free mass spectrometry analysis. A total of 5,417 proteins were sequenced in the different samples. Through supervised analysis, we identified a total of 1302 differential expressed proteins in tumors as compared to non-tumor livers (FC +2 and FDR <0.01). A total of 246 proteins of them (19%) were commonly differently expressed in all tumors types; having HEMNOS a mixture of HB and HCC protein profiling. A panel of potential diagnostic biomarkers including 179, 120 and 81 upregulated proteins (FC >2) was defined for HB, HCC and HEM-NOS, respectively. Hierarchical unsupervised clustering and principal component analysis showed two main cluster of tumors: one including HB and HEM-NOS and another one with a mixture of HB, HEM-NOS and HCC. Interestingly, this second cluster was associated with clinical and molecular features of aggressive tumors such as multifocality (p = 0.029), Epigenetic Epi-CB subclass (p = 0.006), high-risk Molecular Risk Stratification (p = 0.009) and poor survival (log rank test=0.012). A total of 2082 proteins were found to be differently expressed between the two prognostic clusters (FC +2 and FDR < 0.01); the GEO enrichment analysis revealed that these proteins were significantly enriched in post-transcriptional gene silencing and RNA splicing mechanisms (FDR <10−7). In addition, a 25-protein signature associated to liver cancer prognosis was defined (FC>6 and FDR < 10−14). In conclusion, we identified a list of potential diagnostic and prognostic protein biomarkers that after a validation in large patient cohort, could be used to improve the clinical management of childhood liver cancer.
Citation Format: Álvaro Del Río-Álvarez, Juan Carrillo-Reixach, Laura Royo, Montse Domingo-Sàbat, Mikel Azkargorta, Roland Kapler, Stefano Cairo, Christian Vokuhl, Ronald de Krijger, Rita Alaggio, Marta Garrido, Gabriela Guillen, Constantino Sábado, Laura Guerra, Francisco Hernandez, Maria Elena Mateos, Manuel López-Satamaría, Barbara Torres, Maria Pilar Abad, Bajčiová Viera, Piotr Czauderna, Marie Annick Buendia, Felix Elortza, Keith Wheatley, Bruce Morland, Carolina Armengol. Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr PO011.
Collapse
Affiliation(s)
- Álvaro Del Río-Álvarez
- 1Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain., Badalona, Spain,
| | - Juan Carrillo-Reixach
- 1Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain., Badalona, Spain,
| | - Laura Royo
- 1Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain., Badalona, Spain,
| | - Montse Domingo-Sàbat
- 2Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, Badalona, Spain,
| | - Mikel Azkargorta
- 3Proteomics Platform, CIC bioGUNE - ProteoRed-ISCIII, Derio, Spain., Derio, Spain,
| | - Roland Kapler
- 4Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Lindwurmstr. 2a, 80337 Munich, Germany., Munich, Germany,
| | | | - Christian Vokuhl
- 6Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany., Bonn, Germany,
| | - Ronald de Krijger
- 7Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands., Utrecht, Netherlands,
| | - Rita Alaggio
- 8Unit of Pathology, Children's Hospital Bambino Gesù IRCCS, Rome, Italy., Rome, Italy,
| | - Marta Garrido
- 9Hospital Vall d’Hebron, Pathology Department, Barcelona, Spain, Barcelona, Spain,
| | - Gabriela Guillen
- 10Hospital Vall d’Hebron, Pediatric Surgery Department, Barcelona, Spain, Barcelona, Spain,
| | - Constantino Sábado
- 11Hospital Vall d’Hebron, Pediatric Oncology Department, Barcelona, Spain, Barcelona, Spain,
| | - Laura Guerra
- 12University Hospital La Paz, Pathology Department, Madrid, Spain, Madrid, Spain,
| | - Francisco Hernandez
- 13University Hospital La Paz, Pediatric Surgery Department, Madrid, Spain, Madrid, Spain,
| | - Maria Elena Mateos
- 14Pediatric Oncology Unit, Department of Pediatrics, University Hospital Reina Sofía, Córdoba, Spain, Cordoba, Spain,
| | - Manuel López-Satamaría
- 13University Hospital La Paz, Pediatric Surgery Department, Madrid, Spain, Madrid, Spain,
| | - Barbara Torres
- 15Medical Oncology Department, Pediatric Oncology Department, University Hospital La Fe, Valencia, Spain, Valencia, Spain,
| | - Maria Pilar Abad
- 16University Hospital Germans Trias i Pujol, Pediatric Surgery Department, Badalona, España., Badalona, SA, Spain,
| | - Bajčiová Viera
- 17Department of Pediatric Oncology, Childrens University Hospital Brno, Brno, Czech., Brno, Czech Republic,
| | - Piotr Czauderna
- 18Department of Surgery and Urology for Children and Adolescents, Medical University of Gdansk, Gdansk, Poland., Gdansk, Poland,
| | - Marie Annick Buendia
- 19INSERM, UMR 1193, Paul-Brousse Hospital, Hepatobiliary Centre F-94800 Villejuif France., Villejuif, France,
| | - Felix Elortza
- 3Proteomics Platform, CIC bioGUNE - ProteoRed-ISCIII, Derio, Spain., Derio, Spain,
| | - Keith Wheatley
- 20University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham, Birmingham, United Kingdom,
| | - Bruce Morland
- 21Department of Oncology, Birmingham Women's and Children's Hospital, Birmingham, UK, Birmingham, United Kingdom
| | - Carolina Armengol
- 1Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain., Badalona, Spain,
| |
Collapse
|
2
|
Mateos ME, López-Laso E, Vicente J, Ortega R, Vázquez F, Pérez-Navero JL. Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1. Pediatr Int 2020; 62:857-859. [PMID: 32027426 DOI: 10.1111/ped.14183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 10/18/2019] [Accepted: 02/03/2020] [Indexed: 12/14/2022]
Affiliation(s)
- Maria Elena Mateos
- Pediatric Oncology Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain.,Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain
| | - Eduardo López-Laso
- Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain.,Neuropediatric Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain
| | - Josefina Vicente
- Pediatric Radiology Unit, Department of Radiology, Reina Sofia University Hospital, Córdoba, Spain
| | - Rosa Ortega
- Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain.,Department of Pathology, Reina Sofia University Hospital, Córdoba, Spain
| | - Fernando Vázquez
- Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain.,Department of Pediatric Surgery, Reina Sofia University Hospital, Córdoba, Spain
| | - Juan Luis Pérez-Navero
- Pediatric Oncology Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain.,Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain
| |
Collapse
|
3
|
Brock PR, Childs M, Rajput K, Maibach R, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Fabre M, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB): SIOPEL 6. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.10514] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Kaukab Rajput
- Great Ormond Street Hospital for Sick Children, London, United Kingdom
| | - Rudolf Maibach
- International Breast Cancer Study Group, Bern, Switzerland
| | - Derek Roebuck
- Great Ormond Street Hospital, London, United Kingdom
| | | | | | - Milind Ronghe
- Royal Hospital for Sick Children, Glasgow, United Kingdom
| | - Patrizia dall'Igna
- Paediatric Haematology Oncology Division, University of Padova, Padova, Italy
| | | | | | - Jane Skeen
- Starship Children's Hospital, Auckland, New Zealand
| | | | - Monique Fabre
- Institut de Cancerologie Gustave Roussy, Villejuif, France
| | | | | | - Bruce Morland
- University of Birmingham, Birmingham, United Kingdom
| | | |
Collapse
|
4
|
Brock PR, Maibach R, Childs M, Rajput K, Neuwelt EA, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Lockwood L, dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Fabre M, Rangaswami AA, Capra M, Czauderna P, Morland B. Anti-tumor efficacy in SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.10039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Rudolf Maibach
- International Breast Cancer Study Group, Bern, Switzerland
| | | | - Kaukab Rajput
- Great Ormond Street Hospital for Sick Children, London, United Kingdom
| | | | - Derek Roebuck
- Great Ormond Street Hospital, London, United Kingdom
| | | | | | - Milind Ronghe
- Royal Hospital for Sick Children, Glasgow, United Kingdom
| | | | - Patrizia dall'Igna
- Paediatric Haematology Oncology Division, University of Padova, Padova, Italy
| | | | | | - Jane Skeen
- Starship Children's Hospital, Auckland, New Zealand
| | | | - Monique Fabre
- Institut de Cancerologie Gustave Roussy, Villejuif, France
| | | | - Michael Capra
- Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | | | - Bruce Morland
- Birmingham Children's Hospital, Birmingham, United Kingdom
| |
Collapse
|